TrialAdvances in therapy2026

One Subcutaneous 2-ml Injection of Mirikizumab is Bioequivalent to Two 1-ml Subcutaneous Injections in Healthy Participants.

Yuki Otani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.